MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Phase 4
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: pantoprazole
Drug: Pradaxa, within 30 minutes after a meal
Drug: Pradaxa (dabigatran etexilate)
First Posted Date
2011-12-16
Last Posted Date
2015-10-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1067
Registration Number
NCT01493557
Locations
🇺🇸

1160.128.1011 Boehringer Ingelheim Investigational Site, Kalispell, Montana, United States

🇺🇸

1160.128.1041 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States

🇺🇸

1160.128.1068 Boehringer Ingelheim Investigational Site, Roswell, Georgia, United States

and more 100 locations

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Prazaxa
First Posted Date
2011-12-13
Last Posted Date
2018-01-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6772
Registration Number
NCT01491178
Locations
🇯🇵

Boehringer Ingelheim Investigational Site 287, Adachi,Tokyo, Japan

🇯🇵

Boehringer Ingelheim Investigational Site 288, Adachi,Tokyo, Japan

🇯🇵

Boehringer Ingelheim Investigational Site 291, Adachi,Tokyo, Japan

and more 1161 locations

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
Drug: tiotropium
First Posted Date
2011-12-01
Last Posted Date
2014-06-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
140
Registration Number
NCT01483625
Locations
🇺🇸

205.479.01037 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States

🇺🇸

205.479.01007 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States

🇺🇸

205.479.01002 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States

and more 24 locations

Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 144807
Drug: BI 144807 Placebo
First Posted Date
2011-11-29
Last Posted Date
2013-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
74
Registration Number
NCT01480648
Locations
🇩🇪

1313.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

GLORIA-AF Registry Program - Second and Third Phases

Completed
Conditions
Stroke
Atrial Fibrillation
First Posted Date
2011-11-09
Last Posted Date
2021-03-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
37235
Registration Number
NCT01468701
Locations
🇺🇸

Saint Joseph's Research Institute, Atlanta, Georgia, United States

🇺🇸

Seidman Clinical Trials, Delray Beach, Florida, United States

🇺🇸

Universal Clinical Research Associates, Doral, Florida, United States

and more 657 locations

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2
Completed
Conditions
Lung Neoplasms
Interventions
First Posted Date
2011-11-08
Last Posted Date
2020-04-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
319
Registration Number
NCT01466660
Locations
🇫🇷

CTR Leon Berard, Lyon, France

🇬🇧

Western General Hospital, Edinburgh, United Kingdom

🇨🇳

Cancer Hospital of Chinese Academy of Medical Science, Beijing, China

and more 60 locations

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

Phase 2
Withdrawn
Conditions
Asthma
Interventions
Drug: BI 54903
Drug: BI 54903 MD
Drug: Placebo matching Respimat
First Posted Date
2011-10-25
Last Posted Date
2013-10-31
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT01458886

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Phase 2
Withdrawn
Conditions
Asthma
Interventions
Drug: Placebo matching Respimat
Drug: BI 54903 MD
Drug: BI 54903 HD
First Posted Date
2011-10-25
Last Posted Date
2011-11-23
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT01458912

Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2011-10-14
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT01451775
Locations
🇩🇪

1245.79.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Dabigatran Etexilate in Patients With Mechanical Heart Valves

First Posted Date
2011-10-14
Last Posted Date
2014-08-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
328
Registration Number
NCT01452347
Locations
🇧🇪

1160.113.32005 Boehringer Ingelheim Investigational Site, Gent, Belgium

🇨🇿

1160.113.42001 Boehringer Ingelheim Investigational Site, Prague 5, Czech Republic

🇧🇪

1160.113.32007 Boehringer Ingelheim Investigational Site, Brussel, Belgium

and more 37 locations
© Copyright 2025. All Rights Reserved by MedPath